Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
about
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint BlockadeOncolytic viruses as anticancer vaccinesNK cells in the tumor microenvironment.Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapyHarnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsVesicular stomatitis virus modified with single chain IL-23 exhibits oncolytic activity against tumor cells in vitro and in vivo.Viral infection of implanted meningeal tumors induces antitumor memory T-cells to travel to the brain and eliminate established tumors.Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells.Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade gliomaVirotherapy, gene transfer and immunostimulatory monoclonal antibodies.AMP-activated protein kinase is required for the macropinocytic internalization of ebolavirus.Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.Immunomodulatory therapy for melanoma: ipilimumab and beyondInhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.Modulation of CTLA-4 and GITR for cancer immunotherapy.Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.Targeting Melanoma with Cancer-Killing Viruses.Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity.Oncolytic Immunotherapy for Treatment of Cancer.Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activityCytokine-modified VSV is attenuated for neural pathology, but is both highly immunogenic and oncolytic.Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.Viroimmunotherapy for Colorectal Cancer: Clinical Studies.Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.
P2860
Q26769977-2F79875B-68E1-436C-A8F0-FF6E73578C5DQ27025600-A6911910-232E-4785-9B47-8681075CC7B6Q27692606-F5A9F267-D82E-4495-90E4-B9ADCFEBEC38Q28083766-E7C765FB-0ACE-4019-938E-82913FEAD1FEQ28086999-6EE65508-95A9-48AC-92BE-1EDCFCB8A615Q33913506-074E7B51-41B3-4644-823E-B5EF494F03BBQ35788807-A73D5EDF-1843-42B8-8393-D58A5B3FCCA3Q35840314-35E10997-0849-400D-BCAD-AA33582B2F59Q35939421-71A7C12D-BF37-4116-A457-634239B1BBA2Q36456487-53938860-5D2C-4DE8-A82B-2C6E3BEAD455Q36559650-86F5F879-D468-448B-B218-A6D064B64F59Q36664213-42674A9C-3F83-493B-B3E9-DFAFFE534CF2Q36700481-19BE504D-F26B-4E4D-B56F-CBD6B45B2B29Q36751597-B36B875B-130F-459D-81AC-1F2C61B43C82Q36841621-17D2D419-8D84-4232-90A4-72D66E682BE2Q37198935-0F98E706-CBC5-4A8D-B422-B2EA2A7947C8Q37561072-0D6F173B-D5DD-4807-AB4E-056C1BBB85EBQ37766483-EE53AFD7-71F2-414B-B369-3A33E9A030EBQ38194135-49DE99FE-679D-461A-A59E-4C605923F55FQ38241666-B0E49688-3BD9-4B99-8FED-CFB5005B95C4Q38676416-0FA2708D-0648-4948-B228-7A4C2BD26534Q38845078-105B46E2-351D-46CA-A112-AD35F5275C10Q38848223-EAE0368F-E411-4551-A17E-4DD9C5B902D9Q41770092-2BCE66B4-5D59-4660-898D-C26A39EE6A88Q41829468-A6881F47-BA10-4171-A2AE-82101FF9B587Q52688581-AFAC4FB8-782B-4B04-84C3-EB8BC1D577A4Q54221621-A55AD50D-3B6D-4DA2-A4BE-1EDEB3D55065Q55085114-D353ED1B-25B4-44E1-91CC-E793A27E4C9FQ55509278-1A2D8876-1388-4058-A6CE-535605A97F4A
P2860
Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Recombinant vesicular stomatit ...... ates implanted mammary tumors.
@en
Recombinant vesicular stomatit ...... ates implanted mammary tumors.
@nl
type
label
Recombinant vesicular stomatit ...... ates implanted mammary tumors.
@en
Recombinant vesicular stomatit ...... ates implanted mammary tumors.
@nl
prefLabel
Recombinant vesicular stomatit ...... ates implanted mammary tumors.
@en
Recombinant vesicular stomatit ...... ates implanted mammary tumors.
@nl
P2093
P2860
P356
P1433
P1476
Recombinant vesicular stomatit ...... ates implanted mammary tumors.
@en
P2093
J A Griffin
M A Barmada
P Whitaker-Dowling
P2860
P2888
P356
10.1038/CGT.2008.55
P50
P577
2008-07-25T00:00:00Z